Anti-interleukin-2 receptor antibodies in transplantation: What is the basis for choice?

Drugs

Volumn 64, Issue 16, 2004, Pages 1737-1741

  Van Gelder, Teun ^a   Warlé, Michiel ^a   Ter Meulen, Rik G ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

BODY WEIGHT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HYPERSENSITIVITY REACTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; OPPORTUNISTIC INFECTION; PERIPHERAL LYMPHOCYTE; RECEPTOR BLOCKING; REVIEW;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III; DRUG MONITORING; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION IMMUNOLOGY;

EID: 4544326200     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464160-00001     Document Type: Review

References (31)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-12
2. Waldmann TA. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med 1992; 116: 148-60
3. Waldmann TA, O'Shea J. The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10: 507-12
4. Thaczuk J, Yu CL, Baksh S, et al. Effect of anti-IL-2Rα antibody on IL-2-induced Jak/STAT signaling. Am J Transplant 2002; 2: 31-40
5. Vincenti F, Nashan B, Light S, et al. Daclizumab: outcome of phase III trials and mechanism of action. Transpl Proc 1998; 30: 2155-8
6. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclocal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789-94
7. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77: 166-76
8. Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568-73
9. Bumgardner GL, Hardie I, Johnson RW, et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001; 72: 839-45
10. Moser MAJ. Options for induction immunosuppression in liver transplant recipients. Drugs 2002; 62: 995-1011
11. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454-60
12. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342: 613-9
13. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host-disease. Blood 2000; 95: 83-9
14. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002; 62: 879-89
15. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients: CHIB 201 International Study Group. Lancet 1997; 350: 1193-8
16. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody: United States Simulect Renal Study Group. Transplantation 1999; 67: 276-84
17. Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplantation 1999; 68: 1288-94
18. Kovarik JM, Offner G, Broyer M, et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. Transplantation 2002; 74: 966-71
19. Pascual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant 2001; 16: 1756-60
20. Vincenti F, Pace D, Birnbaum J, et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003; 3: 50-2
21. ter Meulen CG, Riemsdijk-van Overbeeke IC, Hene RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective randomized multicenter study. Am J Transplant 2004; 4: 803-10
22. ter Meulen CG, Baan CC, Hene RJ, et al. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralfa chain blockade [letter]. Transplantation 2001; 72: 1709-10
23. Stratta RJ, Alloway RR, Lo A, et al. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003; 75: 1260-6
24. Koch M, Niemeyer G, Patel I, et al. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002; 73: 1640-6
25. Kovarik J, Breidenbach T, Gerbeau C, et al. Disposition and immunodynamics if basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998; 64: 66-72
26. ter Meulen CG, Goertz JHC, Klasen IS, et al. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab. Kidney Int 2003; 64: 697-704
27. Kovarik JM, Moore R, Wolf P, et al. Screening for basiliximab exposure-response relationships in renal transplantation. Clin Transplant 1999; 13: 32-8
28. Keown PA, Balshaw R, Krueger H, et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 71: 1573-9
29. Walters SJ, Whitfield M, Akehurst RL, et al. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients. Pharmacoeconomics 2003; 21: 129-38
30. Leonard PA, Woodside KJ, Gugliuzza KK, et al. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation 2002; 74: 1697-700
31. Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monocloncal antibody basiliximab. Transplantation 2003; 76: 459-63